{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000074","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-08-26T13:17:16+00:00","discovered_at":"2026-08-26T13:18:00.402008+00:00","generated_at":"2026-08-26T13:18:33.779783+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit partner Akeso reports positive Phase III HARMONi-GI1 results for ivonescimab in biliary tract cancer","bullets":["Akeso announced ivonescimab plus chemo showed statistically significant overall survival benefit vs durvalumab plus chemo in first-line advanced BTC.","HARMONi-GI1, a Phase III study in China sponsored by Akeso, also met key secondary endpoints of progression-free survival and objective response rate.","This is the first known Phase III study in advanced BTC to show OS superiority against an anti-PD-(L)1 plus chemotherapy regimen.","Detailed safety and efficacy results will be presented at an upcoming medical congress and published in a peer-reviewed journal.","Ivonescimab remains investigational in Summit's territories including U.S. and Europe; it is approved for NSCLC in China."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000074","json":"https://secwatch.observer/filing/0001599298-26-000074.json","markdown":"https://secwatch.observer/filing/0001599298-26-000074.md","text":"https://secwatch.observer/filing/0001599298-26-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/0001599298-26-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T13:18:33.779783+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}